CELL INTELLIGENCE · 肿瘤细胞治疗研究

ROBO1 CAR-NK92 细胞中 Cbl-b 敲除增强其抗肿瘤疗效

Ablation of Cbl-b in ROBO1 CAR-NK92 Cells Enhances Their Antitumor Efficacy.

CAR-T 疗法在实体瘤中的应用：当前机遇与挑战

Application of CAR-T therapy in solid tumors: current opportunities and challenges.

CRISPR 在医学中的应用：临床试验与治疗应用的系统综述

CRISPR in Medicine: A Systematic Review of Clinical Trials and Therapeutic Applications.

携带 IL-21-siRNA-CCR2 共表达质粒的减毒沙门氏菌增强荷肺癌小鼠的抗肿瘤免疫应答

Attenuated Salmonella Carrying IL-21-siRNA-CCR2 Co-expression Plasmid Enhances Anti-tumor Immune Response in Lung Cancer-bearing Mice.

联合治疗不仅直接抑制了肿瘤细胞的增殖，还增强了荷瘤小鼠的整体抗肿瘤免疫反应。在后续研究中，将进一步验证该治疗在多种肿瘤细胞系中的疗效。IL-21 与 CCR2 阻断联合发挥协同抗肺癌作用。

人源化 ROBO1 CAR 整合至 NK 细胞 PD-1 位点对非小细胞肺癌产生协同杀伤肿瘤效应

Integration of humanized ROBO1 CAR in PD-1 locus in natural killer cells delivers synergistic tumor-killing effect against non-small cell lung cancer.

肺癌基因治疗的进展：从遗传学洞见到临床应用

Advancements in gene therapy for lung cancer: from genetic insights to clinical applications.

非小细胞肺癌基因治疗的进展：当前方法与未来前景

Advancements in Gene Therapy for Non-Small Cell Lung Cancer: Current Approaches and Future Prospects.

靶向肺癌中的 EGFR-TKI 耐药：负载 miR-5193/miR-149-5p 的 NK-EVs 与卡铂联合的作用

Targeting EGFR-TKI resistance in lung cancer: Role of miR-5193/miR-149-5p loaded NK-EVs and Carboplatin combination.

免疫肿瘤学重演个体发育：癌症的现代细胞与基因治疗

Immuno-oncology recapitulates ontogeny: Modern cell and gene therapy for cancer.

NPRL2 基因治疗在人源化小鼠模型中诱导 KRAS/STK11 突变型抗 PD1 耐药转移性非小细胞肺癌（NSCLC）的有效抗肿瘤免疫

NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a hum